

NCT01803438 comparison:

Summary:
CHIA has 39 criteria while your personal folder has 39 criteria
Total found criteria: 39/39
Total not Found: 0/39
Total Extra: 3
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Subject has been diagnosed with symptomatic        │ Subject has been diagnosed with symptomatic        │
│ paroxysmal atrial fibrillation as defined above    │ paroxysmal atrial fibrillation as defined above    │
│ and at least two symptomatic episodes in the last  │ and at least two symptomatic episodes in the last  │
│ six months prior to inclusion                      │ six months prior to inclusion                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ At least one episode of AF must be documented      │ At least one episode of AF must be documented      │
│ during the prior year by any kind of ECG recording │ during the prior year by any kind of ECG recording │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has structural normal heart with an LVEF = │ Subject has structural normal heart with an LVEF ≥ │
│ 50%, thickness of the inter-ventricular septum =12 │ 50%, thickness of the inter-ventricular septum ≤12 │
│ mm and left atrium diameters (short axis) < 46 mm  │ mm and left atrium diameters (short axis) \< 46 mm │
│ obtained by transthoracic echocardiography         │ obtained by transthoracic echocardiography         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has normal ECG parameters (QRS width in    │ Subject has normal ECG parameters (QRS width in    │
│ the 12 channel surface ECG =120 ms, QTc - interval │ the 12 channel surface ECG ≤120 ms, QTc - interval │
│ < 440 ms, PQ - interval = 210 ms; all parameters   │ \< 440 ms, PQ - interval ≤ 210 ms; all parameters  │
│ should be measured at sinus rhythm)                │ should be measured at sinus rhythm)                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is at least 18 and not older than 75years  │ Subject is at least 18 and not older than 75years  │
│ old                                                │ old                                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is able and willing to give informed       │ Subject is able and willing to give informed       │
│ consent                                            │ consent                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has documented typical atrial flutter      │ Subject has documented typical atrial flutter      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has any history of successful or           │ Subject has any history of successful or           │
│ unsuccessful treatment of AF with class I or III   │ unsuccessful treatment of AF with class I or III   │
│ antiarrhythmic or sotalol with the intention to    │ antiarrhythmic or sotalol with the intention to    │
│ prevent an AF recurrence. Patients pretreated with │ prevent an AF recurrence. Patients pretreated with │
│ above AAD at maximum 48 hours with the intention   │ above AAD at maximum 48 hours with the intention   │
│ to convert an AF episode are allowed               │ to convert an AF episode are allowed               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject had any previous left atrial ablation      │ Subject had any previous left atrial ablation      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject had any previous cardiac surgery, e.g.     │ Subject had any previous cardiac surgery, e.g.     │
│ prosthetic valves                                  │ prosthetic valves                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has permanent pacemaker or defibrillator   │ Subject has permanent pacemaker or defibrillator   │
│ implant                                            │ implant                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has 2° type II, 3° degree AV-block or      │ Subject has 2° type II, 3° degree AV-block or      │
│ left/right bundle branch block pattern             │ left/right bundle branch block pattern             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has unstable angina pectoris               │ Subject has unstable angina pectoris               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has history of previous myocardial         │ Subject has history of previous myocardial         │
│ infarction or percutaneous intervention during the │ infarction or percutaneous intervention during the │
│ last three months                                  │ last three months                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has symptomatic carotid stenosis           │ Subject has symptomatic carotid stenosis           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has chronic obstructive pulmonary disease  │ Subject has chronic obstructive pulmonary disease  │
│ with detected pulmonary hypertension or any other  │ with detected pulmonary hypertension or any other  │
│ evidence of significant lung disease               │ evidence of significant lung disease               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has any contraindication for oral          │ Subject has any contraindication for oral          │
│ anticoagulation                                    │ anticoagulation                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has any history of previous transient      │ Subject has any history of previous transient      │
│ ischemic attack or stroke                          │ ischemic attack or stroke                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has known intra-cardiac thrombus formation │ Subject has known intra-cardiac thrombus formation │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has any significant congenital heart       │ Subject has any significant congenital heart       │
│ defect corrected or not (except for patent foramen │ defect corrected or not (except for patent foramen │
│ ovale that is allowed)                             │ ovale that is allowed)                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has evidence of congestive heart failure   │ Subject has evidence of congestive heart failure   │
│ (NYHA class II, III or IV) in sinus rhythm         │ (NYHA class II, III or IV) in sinus rhythm         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has hypertrophic cardiomyopathy            │ Subject has hypertrophic cardiomyopathy            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has abnormal long or short QT interval,    │ Subject has abnormal long or short QT interval,    │
│ signs of Brugada syndrome, known inheriting ion    │ signs of Brugada syndrome, known inheriting ion    │
│ channel disease on the family, arrhythmogenic      │ channel disease on the family, arrhythmogenic      │
│ right ventricular dysplasia                        │ right ventricular dysplasia                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has sarcoidosis                            │ Subject has sarcoidosis                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has pulmonary vein stent                   │ Subject has pulmonary vein stent                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has myxoma. Exclusion criteria based on    │ Subject has myxoma. Exclusion criteria based on    │
│ laboratory abnormalities                           │ laboratory abnormalities                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has thrombocytosis (platelet count >       │ Subject has thrombocytosis (platelet count \>      │
│ 600,000 / µl) or thrombocytopenia (platelet count  │ 600,000 / μl) or thrombocytopenia (platelet count  │
│ <100,000 / µl)                                     │ \<100,000 / μl)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has any untreated or uncontrolled          │ Subject has any untreated or uncontrolled          │
│ hyperthyroidism or hypothyroidism                  │ hyperthyroidism or hypothyroidism                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has renal dysfunction with glomerular      │ Subject has renal dysfunction with glomerular      │
│ filtration rate < 60 ml / min                      │ filtration rate \< 60 ml / min                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has known cryoglobulinaemia. General       │ Subject has known cryoglobulinaemia. General       │
│ exclusion criteria                                 │ exclusion criteria                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has a reversible causes for AF like        │ Subject has a reversible causes for AF like        │
│ hyperthyroidism and alcoholism                     │ hyperthyroidism and alcoholism                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is a pregnant woman or woman of            │ Subject is a pregnant woman or woman of            │
│ childbearing potential not on adequate birth       │ childbearing potential not on adequate birth       │
│ control: only woman with a highly effective method │ control: only woman with a highly effective method │
│ of contraception [oral contraception or intra-     │ of contraception \[oral contraception or intra-    │
│ uterine device] (who must have a negative          │ uterine device\] (who must have a negative         │
│ pregnancy test within 1 week of the start of the   │ pregnancy test within 1 week of the start of the   │
│ therapy) or sterile woman can be enrolled          │ therapy) or sterile woman can be enrolled          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is a breastfeeding woman                   │ Subject is a breastfeeding woman                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has an active systemic infection           │ Subject has an active systemic infection           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is employed by Medtronic or by the         │ Subject is employed by Medtronic or by the         │
│ department of any of the investigators or is a     │ department of any of the investigators or is a     │
│ close relative of any of the investigators         │ close relative of any of the investigators         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is unwilling or unable to comply fully     │ Subject is unwilling or unable to comply fully     │
│ with study procedures and follow-up due to any     │ with study procedures and follow-up due to any     │
│ disease condition, which can raise doubt about     │ disease condition, which can raise doubt about     │
│ compliance and influencing the study outcome       │ compliance and influencing the study outcome       │
│ especially any kind of cancer, severe bleeding in  │ especially any kind of cancer, severe bleeding in  │
│ history or a suspected pro-coagulant state         │ history or a suspected pro-coagulant state         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Legal incapacity or evidence that a subject cannot │ Legal incapacity or evidence that a subject cannot │
│ understand the purpose and risks of the study or   │ understand the purpose and risks of the study or   │
│ inability to comply fully with study procedures    │ inability to comply fully with study procedures    │
│ and follow up                                      │ and follow up                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has a life expectancy of = 1 year          │ Subject has a life expectancy of ≤ 1 year          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is currently enrolled or planning to       │ Subject is currently enrolled or planning to       │
│ participate in a potentially confounding drug or   │ participate in a potentially confounding drug or   │
│ device trial during the course of this study. Co-  │ device trial during the course of this study. Co-  │
│ enrollment in concurrent trials is only allowed    │ enrollment in concurrent trials is only allowed    │
│ when documented pre-approval is obtained from the  │ when documented pre-approval is obtained from the  │
│ Medtronic study manager                            │ Medtronic study manager                            │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                 │
╞═════════════════════════════════════════════════════════════════════════════════════════╡
│ Must have minimum age of 18 Years                                                       │
├─────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 75 Years                                                       │
├─────────────────────────────────────────────────────────────────────────────────────────┤
│ Subject developed persistent AF at least once in history (electrical or pharmacological │
│ cardioversion after 48h or episode duration \>7 days)                                   │
╘═════════════════════════════════════════════════════════════════════════════════════════╛